**Addex Therapeutics Ltd Reports Half-Year 2024 Financial Results and Provides Corporate Update**
Today, Addex Therapeutics Ltd (NASDAQ:ADXN) hosted a conference call to discuss its half-year 2024 financial results and provide a corporate update. The call was led by Co-Founder, Board Director, and Chief Executive Officer Tim Dyer, accompanied by Misha Kalinichev, Head of Translational Science.
Dyer began by expressing gratitude to all attendees for their patience and understanding due to technical issues that affected the presentation’s loading on the webcast system. He directed participants to download the presentation from the website to follow along with the discussion.
Referencing the press release and financial statements issued earlier that day, Dyer highlighted the company’s recent achievements and activities. He emphasized the importance of reviewing the disclaimers, as forward-looking statements would be made during the call based on the company’s current knowledge.
Before handing over to Kalinichev, Dyer provided an overview of Addex Therapeutics’ pipeline, setting the stage for a comprehensive update on the company’s research and development programs.
Leave a Reply